Mammalian‐target of rapamycin inhibition with temsirolimus in myelodysplastic syndromes (MDS) patients is associated with considerable toxicity: results of the temsirolimus pilot trial by the German MDS Study Group (D‐MDS)

Abstract

The mammalian-target of rapamycin (also termed mechanistic target of rapamycin, mTOR) pathway integrates various pro-proliferative and anti-apoptotic stimuli and is involved in regulatory T-cell (TREG) development. As these processes contribute to the pathogenesis of myelodysplastic syndromes (MDS), we hypothesized that mTOR modulation with temsirolimus (TEM) might show activity in MDS. This prospective multicentre trial enrolled lower and higher risk MDS patients, provided that they were transfusion-dependent/neutropenic or relapsed/refractory to 5-azacitidine, respectively. All patients received TEM at a weekly dose of 25 mg. Of the 9 lower- and 11 higher-risk patients included, only 4 (20%) reached the response assessment after 4 months of treatment and showed stable disease without haematological improvement. The remaining patients discontinued TEM prematurely due to adverse events. Median overall survival (OS) was not reached in the lower-risk group and 296 days in the higher-risk group. We observed a significant decline of bone marrow (BM) vascularisation (P = 0·006) but were unable to demonstrate a significant impact of TEM on the balance between TREG and pro-inflammatory T-helper-cell subsets within the peripheral blood or BM. We conclude that mTOR-modulation with TEM at a dose of 25 mg per week is accompanied by considerable toxicity and has no beneficial effects in elderly MDS patients.

Autophagy Activator Drugs: A New Opportunity in Neuroprotection from Misfolded Protein Toxicity

“…Rapamycin and rapalogues are, to date, the most powerful autophagy enhancer agents, although they are loaded with frequent and unwanted effects that currently limit their use to few selected conditions, such as anti-cancer and anti-transplant rejection therapies [244,245]. The recent great surge of scientific interest in autophagy as an anti-aging strategy stimulated the identification of molecular pathways that control the process and led to the definition of new targets for less toxic molecules to be used for long periods under non-life-threatening conditions.…”

The Role of mTOR Inhibitors in Hematologic Disease: From Bench to Bedside

“…Platzbecker et al ( 43 ) treated 19 MDS patients with SRL as a single agent, and demonstrated that SRL might have some activity in patients with more advanced MDS but lacked efficacy in low-risk MDS patients. Martin et al ( 44 ) treated 20 MDS patients with temsirolimus at a weekly dose of 25 mg; however, only four (20%) reached the response assessment after 4 months without hematological improvement. Based on these this response assessment, they concluded that Temsirolimus has no beneficial effects in elderly MDS patients.…”

Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia

“…7,8 PEM was administered according to guidelines for patients with unresectable melanoma at a dose of 2 mg/kg IV over 30 minutes every 3 weeks.…”